Market Research Report
Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||374384|
|Published||Content info||70 Pages
Delivery time: 1-2 business days
|Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 70 Pages||
According to the recently published report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).
The report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Cardiovascular, Oncology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Immunology, Genetic Disorders, Metabolic Disorders and Undisclosed which include indications Arterial Thrombosis, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Alpha-1 Antitrypsin Deficiency (A1AD), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatic Veno-Occlusive Disease, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Neurotoxicity Syndromes, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Thrombotic Microangiopathy, Unspecified and Venous (Vein) Thrombosis.